NF2 and melanoma: Compared to those of mesothelioma and neurologic tumors mentioned earlier, the incidences of NF2 mutations in common human cancers are markedly lower: 4.5% in breast cancer, 4.5–8.3% in colorectal cancer, 5% in melanoma, approximately 2.2% in hepatocellular cancer, 2.2% in acute myelogenous leukemia, and 2.2% in squamous cell lung carcinomas (Fig. 2)39–41.